|
125
|
322
|
5xuiA |
Crystal structure of pde10a in complex with 2-methyl-5-[2-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)et hyl]pyrazolo[1,5-a]pyrimidin-7-ol |
|
121
|
322
|
5xujA |
Crystal structure of pde10a in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine |
|
135
|
353
|
5w6eA |
Pde1b complexed with compound 3s |
|
130
|
338
|
5u7iA |
Pde2 catalytic domain complexed with inhibitors |
|
126
|
307
|
5c29A |
Pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-n-propyl-pyrimidin-4-amine |
|
127
|
323
|
5c2eA |
Pde10 complexed with6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]pyrimidin-4-amine |
|
136
|
325
|
5c28A |
Pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine |
|
126
|
308
|
5c2hA |
Pde10 complexed with 6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine |
|
135
|
325
|
5c1wA |
Pde10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine |
|
133
|
323
|
5c2aA |
Pde10 complexed with 6-chloro-2-cyclopropyl-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin-4-amine |
|
125
|
315
|
5b4lA |
Crystal structure of the catalytic domain of human pde10a complexed with 1-(cyclopropylmethyl)-5-(2-(2,3-dihydro-1h-imidazo[1,2-a]benzimidazol-1-yl)ethoxy)-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one |
|
128
|
321
|
4yqhA |
2-[2-(4-phenyl-1h-imidazol-2-yl)ethyl]quinoxaline (sunovion compound 14) co-crystallized with pde10a |
|
126
|
322
|
4ys7A |
Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3h-imidazo[4,5-f]quinoline (compound 39) with pde10a |
|
137
|
338
|
4htzA |
Crystal structure of pde2 catalytic domain in space group p1 |
|
135
|
338
|
4htxA |
Crystal structure of pde2 catalytic domain in complex with bay60-7550 |
|
133
|
328
|
4e90A |
Human phosphodiesterase 9 in complex with inhibitors |
|
128
|
318
|
4ddlA |
Pde10a crystal structure complexed with novel inhibitor |
|
124
|
307
|
4dffA |
The sar development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10a inhibitors for the treatment of schizophrenia |
|
131
|
340
|
4d09A |
Pde2a catalytic domain in complex with a brain penetrant inhibitor |
|
136
|
339
|
4d08A |
Pde2a catalytic domain in complex with a brain penetrant inhibitor |
|
128
|
325
|
4c1iA |
Selective inhibitors of pde2, pde9, and pde10: modulators of activity of the central nervous system |
|
124
|
312
|
4bbxA |
Discovery of a potent, selective and orally active pde10a inhibitor for the treatment of schizophrenia |
|
140
|
328
|
4ajfA |
Identification and structural characterization of pde10 fragment inhibitors |
|
131
|
320
|
4aelA |
Pde10a in complex with the inhibitor az5 |
|
133
|
324
|
4ajdA |
Identification and structural characterization of pde10 fragment inhibitors |
|
135
|
320
|
4ajmA |
Development of a plate-based optical biosensor methodology to identify pde10 fragment inhibitors |
|
131
|
321
|
4ajgA |
Identification and structural characterization of pde10 fragment inhibitors |
|
123
|
315
|
3wylA |
Crystal structure of the catalytic domain of pde10a complexed with 5-methoxy-3-(1-phenyl-1h-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl)pyridazin-4(1h)-one |
|
125
|
324
|
3wi2A |
Crystal structure of pde10a in complex with inhibitor |
|
136
|
358
|
3wd9A |
Crystal structure of phosphodiesterase 4b in complex with compound 10f |
|
125
|
315
|
3wykA |
Crystal structure of the catalytic domain of pde10a complexed with 3-(1-phenyl-1h-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl)pyridazin-4(1h)-one |
|
123
|
324
|
3ws9A |
Crystal structure of pde10a in complex with a benzimdazole inhibitor |
|
128
|
315
|
3wymA |
Crystal structure of the catalytic domain of pde10a complexed with 1-(2-fluoro-4-(1h-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one |
|
127
|
324
|
3ws8A |
Crystal structure of pde10a in complex with a benzimidazole inhibitor |
|
131
|
358
|
3w5eA |
Crystal structure of phosphodiesterase 4b in complex with compound 31e |
|
123
|
332
|
3v94A |
Tcrpdec1 catalytic domain in complex with inhibitor wyq16 |
|
127
|
332
|
3v93A |
Unliganded structure of tcrpdec1 catalytic domain |
|
137
|
331
|
3v9bA |
Crystal structure of the catalytic domain of pde4d2 with (s)-n-(3-{1-[1-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-2-(1-oxypyridin-4-yl)-ethyl]-1h-pyrazl-3-yl}phenyl)acetamide |
|
124
|
315
|
3ui7A |
Discovery of orally active pyrazoloquinoline as a potent pde10 inhibitor for the management of schizophrenia |
|
126
|
305
|
3uuoA |
The discovery of potent, selectivity, and orally bioavailable pyrozoloquinolines as pde10 inhibitors for the treatment of schizophrenia |
|
135
|
334
|
3tvxA |
The structure of pde4a with pentoxifylline at 2.84a resolution |
|
136
|
327
|
3sl6A |
Crystal structure of the catalytic domain of pde4d2 with compound 12c |
|
129
|
322
|
3snlA |
Highly potent, selective, and orally active phosphodiestarase 10a inhibitors |
|
116
|
325
|
3shzA |
Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors |
|
123
|
322
|
3sniA |
Highly potent, selective, and orally active phosphodiestarase 10a inhibitors |
|
138
|
327
|
3sl3A |
Crystal structure of the apo form of the catalytic domain of pde4d2 |
|
136
|
322
|
3sn7A |
Highly potent, selective, and orally active phosphodiestarase 10a inhibitors |
|
139
|
327
|
3sl8A |
Crystal structure of the catalytic domain of pde4d2 with compound 10o |
|
114
|
325
|
3shyA |
Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors |
|
115
|
323
|
3sieA |
Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors |
